Literature DB >> 17845692

Hepatic resection compared to percutaneous ethanol injection for small hepatocellular carcinoma using propensity score matching.

Yong Beom Cho1, Kuhn Uk Lee, Kyung-Suk Suh, Yoon Jun Kim, Jung-Hwan Yoon, Hyo-Suk Lee, Seokyung Hahn, Byung-Joo Park.   

Abstract

BACKGROUND: Several surgical and non-surgical therapeutic modalities have been used for the treatment of hepatocellular carcinoma (HCC). There have been several studies comparing hepatic resection (HR) and percutaneous ethanol injection (PEI) for the treatment of HCC. However, there is still disagreement about the best treatment modality.
METHODS: From 130 patients undergoing HR, 116 patients were individually matched to 116 controls from 249 patients undergoing PEI using propensity score matching to overcome possible biases in non-randomized study. Survival analyses were undertaken to compare these propensity score-matched groups.
RESULTS: After matching by propensity score, the major clinical outcomes in the HR (n = 116) and the PEI (n = 116) groups were found to be similar. The 1-, 3- and 5-year overall survival rates were higher in the HR group (94.8%, 76.5% and 65.6%) compared to the PEI group (95.7%, 73.5% and 49.3%) (P = 0.059). The cumulative 1-, 3- and 5-year disease-free survival rates showed the same trend (HR: 76.1%, 50.6% and 40.6%; PEI: 62.6%, 25.5% and 19.1%) (P < 0.001). However, when stratified by Child-Pugh classification, it was no longer the case in the Child B patients. Single intrahepatic recurrence was the most common pattern of tumor recurrence after both treatments.
CONCLUSIONS: Patients undergoing HR had a better survival profile than those undergoing PEI. However, when considering which technique to use for optimal HCC management, the individual patient's hepatic function must be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845692     DOI: 10.1111/j.1440-1746.2007.04902.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

1.  Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients.

Authors:  Jia-yan Ni; Lin-feng Xu; Hong-liang Sun; Jing-xing Zhou; Yao-ting Chen; Jiang-hong Luo
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

Review 2.  Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis.

Authors:  Wei Dong; Ting Zhang; Zhen-Guang Wang; Hui Liu
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors.

Authors:  Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

4.  Early effect of hepatic artery TNF-alpha infusion on systemic hemodynamics and inflammation: a dose-response study in pigs.

Authors:  Thilo Schäfer; Jens Sperling; Otto Kollmar; Sven Richter; Martin K Schilling; Michael D Menger; Werner Lindemann
Journal:  Int J Colorectal Dis       Date:  2009-11-04       Impact factor: 2.571

5.  Medical treatment of hepatocellular carcinoma.

Authors:  Alessandro Granito; Luigi Bolondi
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-16       Impact factor: 2.576

6.  Status of primary liver cancer found through routine health check-up.

Authors:  Changhyun Lee; Jong In Yang; Hee Jin Byun; Jung Mook Kang; Seoungho Choi; Jeong Yoon Yim
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

7.  Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis.

Authors:  Hongcui Cao; Lanjuan Li; Guo Tian; Shigui Yang; Jinqiu Yuan; Diane Threapleton; Qiyu Zhao; Fen Chen; Tian'an Jiang
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.